Aurgalys - Abivax SA (ABVX) Abivax, vaincre les maladies infectieuses

Report

Aurgalys

Abivax, vaincre les maladies infectieuses

â€‹Abivax est une sociÃ©tÃ© biopharmaceutique, spÃ©cialisÃ©e dans le dÃ©veloppement d'antiviraux et vaccins contre des maladies infectieuses Ã besoin mÃ©dical non satisfait. GrÃ¢ce Ã un portefeuille solide de produits issus des plateformes propriÃ©taires, ou acquis auprÃ¨s d'organismes de renom (CIGB Ã Cuba, Scripps Institute,CNRS, Institut Curie...), la sociÃ©tÃ© entend devenir dans les annÃ©es Ã venir, un leader dans ce domaine. Deux candidats prometteurs sont actuellement en phases avancÃ©es de dÃ©veloppement clinique, dans l'hÃ©patite B chronique (ABX203) et le VIH/SIDA (ABX464). Abivax commercialisera aussi 3 vaccins prophylactiques acquis auprÃ¨s du Finlay Institute Ã Cuba, lesquels permettront de gÃ©nÃ©rer des revenus rÃ©guliers dÃ¨s 2015, et de prÃ©parer le rÃ©seau commercial pour l'arrivÃ©e des produits propriÃ©taires.

31/08/2015 36 FR

Underlying

Abivax SA

ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

See profile

FR0012333284 Euronext Paris France

Provider

Aurgalys

First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.

See profile

Other Reports on these Companies

GlobeNewsWire

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage ...

April 22, 2025 April 22, 2025 1 EN

GlobeNewsWire

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chr...

April 22, 2025 April 22, 2025 1 EN

EQS Group AG

EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies

EQS-News: ABIVAX / Key word(s): Annual Report Abivax publishes financial reports with the French and U.S. securities regulatory agencies 26.03.2025 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms t...

March 26, 2025 March 26, 2025 1 EN

Biocorp could achieve decisive milestones in 2017

For the past 2 years, Biocorp has initiated major business transformations in order to become a key player in the booming market of connected health. The company has developed a range of connected devices addressing major healthcare issues. The company made significant advances in 2016 by signing 4 partnerships agreements with pharmaceutical players. Based on these agreements, Biocorp and its partners initiated preliminary studies assessing the feasibility and the performance of Biocorpâ€™s connected devices in various indications. Since several milestones are expected on these studies in 201...

January 31, 2017 January 31, 2017 8 EN

Christophe DOMBU

Christophe DOMBU

Implanetâ€™s Jazz sales up 18% in 2016

â€‹ Implanet published its 2016 sales, confirming the good dynamics of its marketing activity (+18% compared to 2015, from â‚¬6.7 M to â‚¬7.8 M). The company benefits from the growing adoption of its lead product, the Jazz Band, especially in France and the US. Given the companyâ€™s efforts to further accelerate the adoption of Jazz, we believe that the company has the means to maintain this trend in 2017. Although the reported sales are slightly below our forecast, we remain confident on the company's outlook and maintain our target price at â‚¬ 2.34 / share.

January 16, 2017 January 16, 2017 2 EN

Christophe DOMBU

Christophe DOMBU

Implanet confirms clinical benefits of Jazz implants after three years of patient follow-up

â€‹Implanet released additional clinical data showing the good performance of the Jazz band implant in correcting large spine deformitiesinadolescents.Datawerepublishedinawhitepaper by French KOLs, giving Implanet additional arguments to convince more surgeons to adopt the companyâ€™s product, while expandingitsscopeofapplication.Implanet recently secured a â‚¬ 6.9Mfollow-onfinancing.Theoperationreceivedastrongsupportfromseinstitutionalinvestorsdespitedifficultmarketconditions.The funds will supportthestrategicdeploymentinitiated by the company to accelerate sales of its spinal implants, which...

December 9, 2016 December 9, 2016 4 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN